DETERMINANTS AND CORRECTION OF INSULIN SECRETION LOSS IN DIABETES
Department: Physiology - Research axis: Translational biology

Research subject

1) Development of an artificial pancreas usable in daily life by patients with Type 1 diabetes : elaboration of innovative model predictive control algorithms, step-by-step evaluation from clinical research centre to home, outpatient experiments. Research programs supported by the Juvenile Diabetes Research Foundation, the FP7 project « Bringing artificial pancreas at home », the AVIESAN Diabeloop project. International Artificial Pancreas Study Group with University of Virginia (USA), University of Padova (Italy), University of Pavia (Italy), University of California-Santa Barbara (USA).

2) Evaluation of intra-peritoneal insulin delivery as an optimal mode of insulin therapy both in open-loop use and as a component of artificial pancreas. Research programs supported by Sanofi, Medtronic, Roche Diagnostics and by the Juvenile Diabetes Research Foundation. French network EVADIAC.

3) Improvement of insulin pump therapy and assessment of benefits in combination with continuous glucose monitoring. Research programs supported by Medtronic, Abbott Diabetes Care. French network EVADIAC-Sensor.

4) Elaboration and development of the concept of blood glucose prediction and online treatment advising to patients with diabetes. Research program supported by the FP7 Project Diadvisor.

5) Innovations in the treatment of Type 1 diabetes: new insulin analogues, telemedicine applied to diabetes (Télésage project), bio-artificial pancreas (FP7 project Biosid), and of Type 2 diabetes: bariatric and metabolic surgery, based upon a better knowledge of molecular mechanisms contributing to the improvement of glucose control (Clinical Research Hospital Project).

 

img.renard.200

Team

Team leader

Éric Renard
PU-PH, CHU


  Hôpital Lapeyronie

  04 67 33 83 82

 

Staff

Jérôme Place
IECN, UM


  Hôpital Lapeyronie

  04 67 33 83 82

 


Major publications

  • Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, Brown SA, Chernavvsky DR, Breton MD, Farret A, Pelletier MJ, Place J, Bruttomesso D, M Del Favero S, Visentin R , Filippi A, Scotton R, Avogaro A, Doyle FJ III. Feasibility of outpatient fully integrated closed-loop control: First studies of wearable artificial pancreas. Diabetes Care2013; 36:1851-8.
  • Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Ocampo Francisco AM, Pei H, Bode B , on behalf of the NN1250-3583 (BEGIN™ BB T1) Trial Investigators. The BEGIN™ Basal-Bolus Type 1 Trial: Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus therapy with mealtime insulin aspart in type 1 diabetes: a 52-week, phase 3, randomised, open-label, multicentre, treat-to-target trial. Lancet 2012; 379: 1489-97.
  • Breton M, Farret A, Bruttomesso D, Anderson S,  Magni L, Patek S,  Dalla Man C, Place J, Demartini S, Del Favero S, Toffanin C, Hughes C, Dassau E, Zisser H, Doyle FJ  III, De Nicolao G, Avogaro A, Cobelli C, Renard E, Kovatchev B, on behalf of The International Artificial Pancreas (iAP) Study Group. Fully-integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near-normoglycemia. Diabetes 2012; 61:2230-2237.
  • Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes 2011 ; 60:2672-82.
  • Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 2010; 33: 121-7.
 

Events

April 2018
Mon Tue Wed Thu Fri Sat Sun
01
02
03
04
05
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30